250 related articles for article (PubMed ID: 16391401)
1. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
Dalakas MC
Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
[TBL] [Abstract][Full Text] [Related]
2. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies.
Dalakas MC
J Neurol; 2005 May; 252 Suppl 1():I19-25. PubMed ID: 15959668
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
Raju R; Dalakas MC
Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
[TBL] [Abstract][Full Text] [Related]
4. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous immune globulin for stiff-person syndrome.
Dalakas MC; Fujii M; Li M; Lutfi B; Kyhos J; McElroy B
N Engl J Med; 2001 Dec; 345(26):1870-6. PubMed ID: 11756577
[TBL] [Abstract][Full Text] [Related]
6. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
Dalakas MC
Neurol Sci; 2003 Oct; 24 Suppl 4():S256-9. PubMed ID: 14598055
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin.
Amemiya K; Semino-Mora C; Granger RP; Dalakas MC
Clin Immunol; 2000 Feb; 94(2):99-104. PubMed ID: 10637094
[TBL] [Abstract][Full Text] [Related]
8. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
9. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
Dalakas MC
Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches in patients with inflammatory myopathies.
Dalakas MC
Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
[TBL] [Abstract][Full Text] [Related]
11. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
Dalakas MC
Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
[TBL] [Abstract][Full Text] [Related]
12. Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.
Dalakas MC
J Neurol; 2006 Sep; 253 Suppl 5():V25-32. PubMed ID: 16998751
[TBL] [Abstract][Full Text] [Related]
13. Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome.
Yi J; Dalakas MC
Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35798561
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.
Quick A; Tandan R
Curr Rheumatol Rep; 2011 Jun; 13(3):192-8. PubMed ID: 21503696
[TBL] [Abstract][Full Text] [Related]
15. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.
Dalakas MC; Sonies B; Dambrosia J; Sekul E; Cupler E; Sivakumar K
Neurology; 1997 Mar; 48(3):712-6. PubMed ID: 9065553
[TBL] [Abstract][Full Text] [Related]
16. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.
Dalakas MC; Koffman B; Fujii M; Spector S; Sivakumar K; Cupler E
Neurology; 2001 Feb; 56(3):323-7. PubMed ID: 11171896
[TBL] [Abstract][Full Text] [Related]
17. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
[TBL] [Abstract][Full Text] [Related]
18. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.
Zschüntzsch J; Voss J; Creus K; Sehmisch S; Raju R; Dalakas MC; Schmidt J
Arthritis Rheum; 2012 Dec; 64(12):4094-103. PubMed ID: 22941914
[TBL] [Abstract][Full Text] [Related]
19. [Current therapy for polymyositis and dermatomyositis].
Chérin P
Rev Med Interne; 2008 Jun; 29 Spec No 2():9-14. PubMed ID: 18927983
[TBL] [Abstract][Full Text] [Related]
20. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Basta M; Dalakas MC
J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
